We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
AMRI Completes Strategic European Acquisition
News

AMRI Completes Strategic European Acquisition

AMRI Completes Strategic European Acquisition
News

AMRI Completes Strategic European Acquisition

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "AMRI Completes Strategic European Acquisition"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Albany Molecular Research, Inc. has announced that it has completed the acquisition of ComGenex, located in Budapest, Hungary.

On January 30, AMRI announced the signing of a stock purchase agreement to acquire ComGenex. The completed acquisition provides AMRI with an immediate presence in Europe.

In combination with AMRI's facilities in the U.S. and Asia, the acquisition enhances the company's ability to offer a range of flexible services and cost models and provides a hub from which to establish additional relationships with European pharmaceutical and biotechnology companies.

"All of us at AMRI welcome ComGenex employees to our team. We look forward to achieving the synergies that can occur when two strong organizations combine resources," said AMRI Chairman, President and CEO Thomas E. D'Ambra, Ph.D.

Advertisement